title: Long-term response to zonisamide in patients with West syndrome.
abstract: The long-term effectiveness of zonisamide (ZNS) was evaluated in 11 patients with West syndrome (7 symptomatic) who had cessation of spasms with ZNS monotherapy. During the follow-up period (24 to 79 months, mean = 53 months), this response was maintained in 7 patients (3 symptomatic, relapse rate = 36%), including 2 children in whom ZNS was successfully discontinued. No serious adverse reactions were noted. ZNS may be both effective and well tolerated for the treatment of West syndrome.
authors.affiliation: Division of Pediatric Neurology, Osaka Medical Center and Research Institute for Maternal and Child Health, Murodo-cho, Izumi, Japan. yasuzuki@mch.pref.osaka.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Imai
authors.forename: Y
authors.initials: Y
authors.lastname: Toribe
authors.forename: H
authors.initials: H
authors.lastname: Ueda
authors.forename: K
authors.initials: K
authors.lastname: Yanagihara
authors.forename: K
authors.initials: K
authors.lastname: Shimono
authors.forename: T
authors.initials: T
authors.lastname: Okinaga
authors.forename: J
authors.initials: J
authors.lastname: Ono
authors.forename: T
authors.initials: T
authors.lastname: Nagai
authors.forename: T
authors.initials: T
authors.lastname: Matsuoka
authors.forename: T
authors.initials: T
authors.lastname: Tagawa
authors.forename: J
authors.initials: J
authors.lastname: Abe
authors.forename: Y
authors.initials: Y
authors.lastname: Morita
authors.forename: Y
authors.initials: Y
authors.lastname: Fujikawa
authors.forename: H
authors.initials: H
authors.lastname: Arai
authors.forename: T
authors.initials: T
authors.lastname: Mano
authors.forename: S
authors.initials: S
authors.lastname: Okada
mesh_terms: D000293:Adolescent; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008134:Long-Term Care / Q000706:statistics & numerical data; D008297:Male; D011446:Prospective Studies; D013036:Spasms, Infantile / Q000188:drug therapy*; D000078305:Zonisamide
chemical_list: D000927:Anticonvulsants; D007555:Isoxazoles; D000078305:Zonisamide